Business
GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results
Data presented at the 2025 American Thoracic Society (ATS) International Conference Pre-clinical and interim clinical results underscore GRI-0621’s potential to have both anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis Results from 6-week interim analysis (n=24) in ongoing Phase 2a study of GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) anticipated in Q2 2025 LA JOLLA, CA, May 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company
About this update from Gri Bio, Inc.
[{"type":"image","alt":"GRI Bio, Inc.","displaySize":"","headline":null,"caption":"GRI Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":298,"height":144,"url":"https://media.zenfs.com/en/globenewswire.com/54d4b237b8db6f5a566b8418ca0ae02c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VpQzftFLIZDIqhYm6TSWfw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/54d4b237b8db6f5a566b8418ca0ae02c","width":298,"height":144}},"lazy":false},{"type":"text","content":"Data presented at the 2025 American Thoracic Society (ATS) International Conference","length":83,"tagName":"p"},{"type":"text","content":"Pre-clinical and interim clinical results underscore GRI-0621’s potential to have both anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis","length":152,"tagName":"p"},{"type":"text","content":"Results from 6-week interim analysis (n=24) in ongoing Phase 2a study of GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) anticipated in Q2 2025","length":161,"tagName":"p"},{"type":"text","content":"LA JOLLA, CA, May 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the presentation of positive preclinical data demonstrating its lead program GRI-0621 has anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis.","length":447,"tagName":"p"},{"type":"text","content":"The data was presented by Marc Hertz, PhD, Chief Executive Officer of GRI Bio in the poster titled, “Inactivation of iNKT Cells After the Inflammatory Phase Leads to Significant Inhibition of Fibroblast Activation and Fibrosis in a Model of Pulmonary Fibrosis,” as part of the D21 - IMMUNOLOGICAL INSIGHTS IN LUNG INFLAMMATION AND REPAIR session at the 2025 ATS International Conference held on Wednesday, May 21, 2025.","length":419,"tagName":"p"},{"type":"text","content":"“We continue believe GRI-0621 is a promising potential treatment option for IPF, an indication where there remains significant unmet need. Our growing body of pre-clinical results continue to bolster our understanding of the role of iNKT cell activity in driving pulmonary fibrosis and further support our ongoi...